GENinCode is a U.K. limited company specializing in risk assessment and prediction of cardiovascular disease. Cardiovascular disease (CVD) is a broad disease classification which includes coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension, venous thromboembolism and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States.
GENinCode products provide genetic information to enable patients and healthcare practitioners to assess and predict the onset of cardiovascular disease. Our tests and reports help inform health care practitioners and patients of their health risk enabling behavioral and lifestyle changes alongside delivering the most effective treatment pathways.
GENinCode U.K. Limited was incorporated in September 2018 and subsequently acquired the products, assets and know-how of the Ferrer inCode and the Gendiag.exe businesses, then part of Ferrer, a large pharmaceutical and healthcare company based in Spain. GEN inCode has a strong, granted intellectual property portfolio with a vision to educate patients on cardiovascular risk assessment using the predictive capability of GEN inCode products and lifestyle choices to help improve patient outcomes.
GENinCode has amassed significant investment over the past 15 years in its research and development of predictive and preventative technology to cardiovascular disease.
GENinCode has developed a proprietary online cloud-based system Sitab® to integrate patients clinical and genetic data and provide online reporting capabilities to health care practitioners.
The Core Products of GEN inCode Include:
GENinCode operates business units in Europe and the United States in the following locations:
GENinCode UK Limited
One, St. Peters Square,
Manchester, United Kingdom, M2 3DE
Rambla Egara, 235 Terrassa ES-08224
Diagonal, 622 Barcelona ES-08021
GENinCode U.S. Inc.
Corporation Trust Center
1209 Orange St, Wilmington, DE 19801 U.S.
Following the initial investment in September 2018 by the Board of GENinCode and Santi 1990 S.L., the GENinCode Group has grown rapidly and is now setting up operations in the US.
At the beginning of 2020 the Company raised a private investment round for £400k and in July 2020 Maven Capital Partners and Downing Investment Trust made a £3.0m foundation investment in GENinCode.
Maven Capital Partners is an independent alternative asset manager, with over £660 million of assets under management and available to invest. Maven was formed in 2009 after a buyout of the Aberdeen Asset Management private equity business, and operates from a nationwide network of regional offices.
Over 25,000 investors trust Downing with over £1 billion of their assets, invested into businesses that make a difference, including renewable energy, care homes, health clubs and children’s nurseries.